hackint0sh/New-Dataset huggingface dataset:
* Improved quality of life, assessed using the OHRQoL (Oral Health Related Quality) scale All endpoints will be evaluated within 12 months. conditions: Malocclusion conditions: Musculoskeletal Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: at correcting malocclusions or restoring the integrity of the dentition name: comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system. measure: Frequency of relapses and repeated requests for correction of disorders bite or restoration of the integrity of the dentition. measure: Change in pain intensity measured by visual analog scale (VAS). measure: Changes in functional parameters of the temporomandibular joint, including range of motion. joint, including range of motion. measure: Improved quality of life, assessed using the OHRQoL (Oral Health Related Quality) scale sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Nmsi Dentmaster city: Novosibirsk state: Novosibirsk Region zip: 630090 country: Russian Federation name: Tatiana A Gatilova role: CONTACT phone: 952939919 phoneExt: +7 email: gatilova@dentservice.ru name: Anastasia V Semivolova role: PRINCIPAL_INVESTIGATOR lat: 55.0415 lon: 82.9346 hasResults: False
nctId: NCT06263491 id: 2023-0413 id: NCI-2024-01325 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2025-03-01 date: 2027-03-01 date: 2024-02-16 date: 2024-03-01 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL. conditions: Mantle Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Rituximab name: Pirtobrutinib measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Preetesh Jain, MBBS, MD, DM, PhD role: CONTACT phone: (713) 563-8786 email: pjain@mdanderson.org name: Preetesh Jain, MBBS, MD, DM, PhD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06263478 id: INCA34176-358 briefTitle: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2025-12-31 date: 2025-12-31 date: 2024-02-16 date: 2024-02-16 name: Incyte Biosciences Japan GK class: INDUSTRY briefSummary: This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD). conditions: Chronic Graft-versus-host-disease studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: INCA034176 measure: Overall Response Rate in the First 6 Cycles measure: Proportion of participants with a ≥ 7-point improvement in modified Lee symptom scale (mLSS) score measure: Overall Response Rate measure: Duration of Response measure: Organ-specific Response Rate measure: Percent reduction in average daily dose (or equivalent) of corticosteroids measure: Proportion of participants who discontinue corticosteroid use measure: Number of participants with Treatment-emergent Adverse Events (TEAEs) measure: Change from baseline in Karnofsky/Lansky performance status measure: Axatilimab pharmacokinetic (PK) in Plasma measure: Number of Participants with Anti-Drug Antibody (ADA) sex: ALL minimumAge: 6 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06263465 id: CALM briefTitle: Precision Vaginal Microbiome Transplantation in Women With Bacterial Vaginosis overallStatus: RECRUITING date: 2024-03-11 date: 2025-07-01 date: 2025-12-31 date: 2024-02-16 date: 2024-03-13 name: Zhujiang Hospital class: OTHER name: ZhuHai Hospital briefSummary: The aim of this study was to explore the efficacy and safety of a new vaginal microbiome transplantation technique, using Lactobacillus cispatus from healthy donors as a treatment of bacterial vaginosis. conditions: Bacterial Vaginosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 120 type: ESTIMATED name: Lactobacillus cispatus name: placebo measure: BV recurrence rate measure: vaginal secretions 16s rRNA gene sequencing measure: BV recurrence rate sex: FEMALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Zhuhai People'S Hospital status: RECRUITING city: Zhuhai state: Guangdong zip: 519050 country: China name: Jingya WU, Doctor role: CONTACT phone: +8615902057821 lat: 22.27694 lon: 113.56778 hasResults: False
nctId: NCT06263452 id: 23-2768 id: 1R01HL157422-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01HL157422-01 briefTitle: Beta-Blocker Influences on Inflammatory and Neural Responses to Stress overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03 date: 2026-03 date: 2024-02-16 date: 2024-03-06 name: University of North Carolina, Chapel Hill class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) name: University of California, Los Angeles name: Dartmouth College briefSummary: The purpose of this study is to map the neural and molecular mechanisms underlying psychological stress-induced changes in inflammation which could reveal new targets for intervention to reduce the risk of cardiovascular disease. conditions: Cardiovascular Disease studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Subjects (n = 60 per condition, N = 120) will either take a one-time, 40mg dose of propranolol or an encapsulated placebo. primaryPurpose: BASIC_SCIENCE masking: TRIPLE maskingDescription: This is a double blind, randomized, placebo-controlled mechanistic clinical trial. The Investigational Drug Service will randomly assign patients to the experimental group (propranolol) or the placebo group. Research staff who have direct contact with the participant will be blind to their condition. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 120 type: ESTIMATED name: Propranolol name: Placebo measure: Change in levels of pro-inflammatory cytokine interleukin-6 in response to social stress measure: Change in levels of inflammatory gene expression in response to social stress sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Social Neuroscience and Health Laboratory city: Chapel Hill state: North Carolina zip: 27514 country: United States name: Keely A Muscatell, PhD role: CONTACT phone: 916-495-7661 email: kmuscatell@unc.edu name: Jessica R Cohen, PhD role: SUB_INVESTIGATOR name: Kristen A Lindquist, PhD role: SUB_INVESTIGATOR name: Samantha E Meltzer-Brody, MD, MPH role: SUB_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06263439 id: RNI 2023 MIRAND id: 2023-A00585-40 type: OTHER domain: ANSM briefTitle: Surveillance of HFMD in Pediatric Outpatients acronym: PMB overallStatus: RECRUITING date: 2023-06-20 date: 2028-06-20 date: 2028-06-20 date: 2024-02-16 date: 2024-02-16 name: University Hospital, Clermont-Ferrand class: OTHER briefSummary: The aims of this prospective multicentric study is to determine the types of enteroviruses (EVs) responsible for hand, foot and mouth disease (HFMD) or herpangina in children seen within an ambulatory setting :
* to describe and compare the epidemiological, demographic, clinical and virological characteristics of these infections between the different types of EV. conditions: Hand, Foot and Mouth Disease conditions: Herpangina conditions: Enterovirus Infections studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 3000 type: ESTIMATED name: Throat/buccal swab sample measure: Prevalence of different types of Enteroviruses measure: Clinical characteristics of HFMD/Herpangina according to the different types of enteroviruses sex: ALL maximumAge: 10 Years stdAges: CHILD facility: CHU de Clermont-Ferrand status: RECRUITING city: Clermont-Ferrand zip: 63000 country: France name: Lise Laclautre role: CONTACT email: promo_interne_drci@chu-clermontferrand.fr name: Audrey Mirand role: PRINCIPAL_INVESTIGATOR lat: 45.77966 lon: 3.08628 hasResults: False
nctId: NCT06263413 id: 24.12.2266-GHM briefTitle: Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions acronym: IDEI_2023 overallStatus: RECRUITING date: 2024-01-15 date: 2024-06-30 date: 2024-09-30 date: 2024-02-16 date: 2024-03-19 name: AI Labs Group S.L class: INDUSTRY name: Instituto de Dermatología Integral (IDEI) briefSummary: Artificial intelligence (AI) based on imaging holds tremendous potential to enhance visual diagnostic accuracy in the medical field. Amid the COVID-19 pandemic, limited access to in-person healthcare services drove shifts in medical care, hastening the adoption of telemedicine. In this context, AI usage for triage and decision support may be crucial for professionals to manage workload and improve performance. In dermatology, pigmented lesions, acne, and alopecia are three recurring pathology groups with high demand in dermatological centers. Both triage, clinical evaluation, and patient follow-up require in-person resources and specialist dedication. Employing tools like AI can benefit these professionals in reducing such processes and optimizing workload.
In this study, the Legit.Health tool, developed by AI LABS GROUP S.L., which utilizes artificial intelligence to optimize clinical flow and patient care processes for skin conditions, will be evaluated. The purpose of this tool is to automatically prioritize patients with greater urgency, assign the type of consultation (dermatological or aesthetic), enhance diagnostic capability and detection of malignant pigmented lesions in auxiliary staff, and provide a visual record (photograph) of the condition for later review by external experts.
Study Population Adult patients (≥ 18 years) with skin pathologies treated at the Dermatology Unit of IDEI. conditions: Acne conditions: Acne Vulgaris conditions: Alopecia, Androgenetic conditions: Pigmented Lesions conditions: Pigmented Skin Lesion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 150 type: ESTIMATED measure: Concordance between the physician's diagnosis and that of the tool. measure: Agreement of detected malignancy between the dermatologist and Legit.Health tool measure: Acne severity measure: Severity of alopecia sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IDEI Hospital status: RECRUITING city: Madrid zip: 28009 country: Spain name: Miguel Sánchez-Viera, PhD role: CONTACT phone: +34 915740990 email: sanchez.viera@ideidermatologia.com name: Miguel Sánchez-Viera, PhD role: PRINCIPAL_INVESTIGATOR name: Concetta Alessandro, MD role: SUB_INVESTIGATOR name: Alejandra Capote, MD role: SUB_INVESTIGATOR name: Pablo López-Andina, MD role: SUB_INVESTIGATOR name: Allison Marie Bell-Smythe Sorg, MD role: SUB_INVESTIGATOR name: Alejandra Vallejos, MD role: SUB_INVESTIGATOR name: Isabel del Campo, MD role: SUB_INVESTIGATOR name: Juliana Machado, MD role: SUB_INVESTIGATOR name: Raúl Lucas-Escobar, MD role: SUB_INVESTIGATOR name: Beatriz Torres role: SUB_INVESTIGATOR name: Alfonso Medela, MsC role: SUB_INVESTIGATOR name: Taig Mac Carthy, MsC role: SUB_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06263400 id: randomized trial briefTitle: Recovery Levels of Depression Patients and Caregiver Psychoeducation overallStatus: RECRUITING date: 2022-09-01 date: 2024-12-30 date: 2024-12-30 date: 2024-02-16 date: 2024-02-16 name: Aydin Adnan Menderes University class: OTHER briefSummary: To determine the effect of psychoeducation given to patients and caregivers on patients' depression and recovery levels, caregivers' emotional expression and family burden levels. conditions: Psychoeducation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In randomization, among the patients who volunteered to participate in the study, the odd number of patients and their caregivers in the list made according to the order of hospitalization constituted the study group, and the even number of patients and their caregivers formed the control group. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 92 type: ESTIMATED name: psychoeducation and follow-up study measure: to patients before training measure: pre-training caregivers measure: after training measure: after training sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AydınAdnan Menderes University, Faculy of Nursing, Division Public Health Nursing status: RECRUITING city: Aydın state: Aydın/Turkey zip: 09000 country: Turkey name: şerife öztaban, MsC role: CONTACT phone: +905557130105 email: serifeoztaban@gmail.com name: Filiz ADANA, Phd role: SUB_INVESTIGATOR lat: 37.84501 lon: 27.83963 hasResults: False
nctId: NCT06263387 id: FILObsLAM_VENAZA briefTitle: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine acronym: VENAZA overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2024-11-30 date: 2025-03-30 date: 2024-02-16 date: 2024-04-18 name: French Innovative Leukemia Organisation class: OTHER name: Acute Leukemia French Association briefSummary: Following the results of the phase 1b and the phase 3 studies, Venetoclax/Azacitidine (VEN/AZA) was available in France for newly diagnosed AML patients ineligible-IC patients through the early access program the so-called ATU program.
nctId: NCT06263361 id: NCH02-2021 briefTitle: Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma. overallStatus: RECRUITING date: 2021-10-01 date: 2026-12-31 date: 2026-12-31 date: 2024-02-16 date: 2024-02-16 name: IRCCS San Raffaele class: OTHER briefSummary: Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non- Hodgkin lymphoma exclusively localized into the nervous system. The aim of this study is to evaluate the MRI imaging characteristics of the peritumoral area (PTA) and to correlate this information to pathological findings. conditions: Cerebral Lymphoma studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 15 type: ESTIMATED name: MRI imaging name: Cerebral biopsy measure: MRI imaging measure: MRI imaging measure: MRI imaging measure: MRI imaging measure: Define immunopathological features measure: Accuracy of fluoresceine guided stereotactic biopsy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS San Raffaele Scientific Institute status: RECRUITING city: Milan zip: 20132 country: Italy name: Laura Sincinelli role: CONTACT phone: 003926435568 email: sincinelli.laura@hsr.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06263348 id: HMM0601 briefTitle: A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes overallStatus: RECRUITING date: 2023-12-20 date: 2026-04-30 date: 2026-04-30 date: 2024-02-16 date: 2024-02-16 name: Hua Medicine Limited class: INDUSTRY name: Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd. briefSummary: The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin. conditions: Type2diabetes studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The marketed product - Dorzagliatin tablet (HuaTangNing®) is used as the study drug. During this study, the dosage and administration of Dorzagliatin tablets will be completely in accordance with the investigator's judgment based on the package insert and the patient's condition. primaryPurpose: TREATMENT masking: NONE count: 2000 type: ESTIMATED name: Dorzagliatin tablets measure: Incidences of ADRs and SAEs measure: Blood glucose indicators measure: Response rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China-Japan Friendship Hospital status: RECRUITING city: Beijing state: Beijing zip: 100029 country: China name: Wenying Yang, MD,PhD role: CONTACT lat: 39.9075 lon: 116.39723 facility: China-Japan Friendship Hospital status: RECRUITING city: Beijing state: Beijing zip: 100029 country: China name: Bo Zhang, MD,PhD role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06263335 id: Fatima Jinnah Women University briefTitle: MBI for Psychological Distress, SI and NSSI Among Young Adults overallStatus: COMPLETED date: 2022-02-28 date: 2022-05-28 date: 2022-05-28 date: 2024-02-16 date: 2024-02-16 name: Fatima Jinnah Women University class: OTHER briefSummary: Designed to measure the impact of Mindfulness Based Intervention on depression, anxiety, stress, psychological distress, Suicidal Ideation, Non-Suicidal Self Injury urge and Mindfulness in young adults. Those individuals who agree to participate in the trial and identified with high levels of psychological distress and Suicidal Ideation, randomly divided into interventional (n=30) and control (n=30) groups. The Mindfulness Based Stress Reduction intervention then administered to the interventional group for eight weeks and pre and post intervention assessment done for both the groups. conditions: Psychological Distress conditions: Suicidal Ideation conditions: Non-Suicidal Self Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ACTUAL name: Mindfulness Based Stress Reduction Intervention measure: Psychological Distress measure: Suicidal Ideation measure: Non-Suicidal Self-Injury (NSSI) sex: ALL minimumAge: 18 Years maximumAge: 24 Years stdAges: ADULT facility: Fatima Jinnah Women University city: Rawalpindi state: Punjab zip: 46000 country: Pakistan lat: 33.6007 lon: 73.0679 hasResults: False
nctId: NCT06263322 id: IRB202200419 id: R21AG073769 type: NIH link: https://reporter.nih.gov/quickSearch/R21AG073769 briefTitle: The ROAMM-EHR Study acronym: ROAMM-EHR overallStatus: RECRUITING date: 2023-11-16 date: 2026-10-17 date: 2026-10-17 date: 2024-02-16 date: 2024-02-16 name: University of Florida class: OTHER name: National Institute on Aging (NIA) briefSummary: In recent years, mobile health (mHealth) apps have promised improved monitoring of health conditions to improve clinical outcomes. The objective of this study is to conduct a pilot randomized clinical trial (RCT) to evaluate the impact of using remotely collected patient generated health data (PGHD) from older patients undergoing bypass surgery due to chronic limb threatening ischemia. The hypothesis is that integrating PGHD with an EHR system will help providers manage post-surgical symptoms and thus improve post-operative mobility and quality of life health outcomes. conditions: Peripheral Arterial Disease conditions: Chronic Limb-Threatening Ischemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Randomized Clinical trial. Comparison study to test the feasibility of patient generated health data compared to standard of care post-surgical observation. primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE maskingDescription: Participants are masked to whether their PGHD are being sent to their care provider. Care providers are masked to who receives standard of care. Investigators (except for one who will be the point person for randomization) will be masked to intervention assignments. Staff assessors will be masked to whether PGHD are being sent to their care provider. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Actionable remotely generated health data name: Non-Actionable remotely generated health data measure: 6-min walk distance measure: self-reported quality of life sex: ALL minimumAge: 60 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Aging status: RECRUITING city: Gainesville state: Florida zip: 32611 country: United States name: Institute_of_Aging role: CONTACT phone: 352-273-5919 email: recruit@aging.ufl.edu name: HOBI_Department role: CONTACT phone: 352.627.9467 email: hobi@health.ufl.edu lat: 29.65163 lon: -82.32483 hasResults: False
nctId: NCT06263309 id: Femoralneckfracture briefTitle: Mid-Term Radiological Outcomes of Femoral Neck Fractures Treated With Osteosynthesis: A Comparative Analysis overallStatus: COMPLETED date: 2022-06-01 date: 2023-06-01 date: 2023-09-01 date: 2024-02-16 date: 2024-02-16 name: Istanbul University class: OTHER briefSummary: OBJECTIVES: This study assesses the efficacy of dynamic hip screw (DHS) versus cannulated screws for femoral neck fractures, focusing on femoral neck shortening, avascular necrosis (AVN) incidence, and functional outcomes.
Outcome Measures and Comparisons: Main outcomes were femoral neck shortening, incidence of AVN, and Harris Hip Score (HHS) for functional assessment. conditions: Femoral Neck Fractures conditions: Femoral Neck Shortening studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 10 type: ACTUAL name: Femoral neck shortening measurement measure: Harris Hip score sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University city: İstanbul zip: 34093 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06263296 id: UW 24-055 briefTitle: Smartphone Assisted Self-management Education for Adult Burn Patient at Aftercare overallStatus: NOT_YET_RECRUITING date: 2024-03-11 date: 2025-06-28 date: 2025-09-30 date: 2024-02-16 date: 2024-03-05 name: Queen Mary Hospital, Hong Kong class: OTHER briefSummary: Burn rehabilitation management is dependent on the patients themselves, non-treatment adherence may delay the optimal timing of burn rehabilitation and it may not be regained easily. The inevitable sequelae of increasing joint stiffness and tethered soft-tissue glide become more devastating over time. It has a major impact on clinical outcomes such as scarring, deformity and dysfunction, which result in lower quality of life compared to general population